RxSight Sees Q2 Revenue Of $32M-$34M; Sees FY2026 Revenue Of $140M-$160M

RxSight, Inc. (NASDAQ: RXST ) today announced select preliminary financial results for the second quarter of 2026 and updates to its standalone product pipeline, following the announcement of the company’s strategic collaboration with Alcon to develop and commercialize light-adjustable Presbyopia-Correcting Intraocular Lenses.

Preliminary Second Quarter 2026 Results Total company revenue is expected to be approximately $32 to $34 million, which includes, $5 to $7 million in revenue recognized from the RxSight Alcon Strategic Collaboration, with the specific amount expected to be reported with the Company’s financial results for the second quarter of 2026 in August 2026.

Sales of approximately $27 million, which includes, the sale of 24,917 Light Adjustable Lens (LAL®) units; and 11 Light Delivery Devices (LDD™) units; 1 rental unit placed.

Cash, cash equivalents and short-term investments of approximately $209 million as of June 30, 2026.

Pipeline Highlights Next-generation RxSight Light Adjustable Technology™ platform, with intermediate-term launches of new LAL®, LAL +®, and LAL Toric lenses with improved workflow and fewer required post-operative treatments.

Collaboration with Alcon to innovate our respective platforms to develop and commercialize light-adjustable Presbyopia-Correcting Intraocular Lenses (Simultaneous Vision Intraocular Lenses). "While we faced meaningful commercial headwinds in Q2, including from more widespread competitive trialing, the unique ability of RxSight’s Light Adjustable Technology to customize visual outcomes continued to deliver significant clinical benefits to thousands of patients around the world," said Dr.

Ron Kurtz, Chief Executive Officer and President of RxSight. "To position the company for deeper penetration of current, next-generation, and collaboration products, we are accelerating investments in our LAL sales force and commercial capabilities, while maintaining a disciplined approach to overall spending.

By leveraging our differentiated technology, large customer base, strong balance sheet and exciting pipeline, we believe RxSight is well positioned to drive both high-margin implant sales and future royalty income, thereby empowering doctors to deliver the industry’s premier outcomes for even more of their patients." Updated Product Pipeline RxSight is developing the first and only suite of adjustable IOLs built on its next-generation Light Adjustable Lens technology platform with improved workflow and enhanced performance.

Highlights include: Next-generation LAL, designed to deliver best-in-class visual quality and optical clarity, with post-operative refractive optimization to consistently achieve targeted visual outcomes; Next-generation LAL+, designed to improve intermediate vision for everyday activities while preserving high-quality optical performance, with adjustability enabling precise refractive targeting; LAL Toric, designed with built-in astigmatism correction, while still enabling post-operative refinement of residual sphere and cylinder to maximize uncorrected visual acuity.

Updated 2026 Guidance 2026 full-year revenue of $140 to $160 million, inclusive of RxSight sales and revenue recognized from the RxSight Alcon Strategic Collaboration, comprised of: Sales of $110 to $120 million, below previous guidance of $120 to $135 million Collaboration Agreement revenue of $30 to $40 million, subject to the terms and conditions described in the Current Report on Form 8-K filed with the Securities and Exchange Commission (SEC) on or about the date hereof; Gross margin of 73% to 75%, above previous guidance of 70% to 72%; and Operating expense at the high-end of $150 to $160 million, in line with previous guidance